Clinical Trials Directory

Trials / Completed

CompletedNCT02644798

Nucleotide Polymorphism in ARDS Outcome

Nucleotide Polymorphism in ARDS Outcome: a Whole Exome Sequencing Association Study

Status
Completed
Phase
Study type
Observational
Enrollment
105 (actual)
Sponsor
Southeast University, China · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Acute respiratory distress syndrome (ARDS) is characterized by increased pulmonary vascular permeability and reduced aerated lung tissue. With an extremely high hospital mortality among 35 - 46%, current therapeutic strategies to increase ARDS survival are still limited. Advances in etiology and pathology of ARDS are urging. Numerous genetic variants were identified associated with ARDS outcome. By whole-exome sequencing association study, our goal was to explore the associations between genetic variants and ARDS outcome.

Detailed description

Acute respiratory distress syndrome (ARDS) is characterized by increased pulmonary vascular permeability and reduced aerated lung tissue. With an extremely high hospital mortality among 35 - 46%, current therapeutic strategies to increase ARDS survival are still limited. Advances in etiology and pathology of ARDS are urging. Numerous genetic variants were identified associated with ARDS outcome. Then a few genetic risk factors have been discovered by large-scale genotyping approaches, from in vivo or in vitro models of lung injury, which highlight the importance of identifying genetic biomarkers of ARDS outcome to further improve stratification. The mutational landscape and variability at single nucleotide polymorphisms (SNP) with ARDS outcome in Chinese is unknown, not to mention their associations. By whole-exome sequencing association study, our goal was to explore the associations between genetic variants and ARDS outcome.

Conditions

Interventions

TypeNameDescription
OTHERBaseline-recorded data recordedBaseline-recorded data recorded. Peripheral blood samples were drawn.

Timeline

Start date
2016-01-01
Primary completion
2016-12-01
Completion
2017-06-30
First posted
2016-01-01
Last updated
2022-03-15

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT02644798. Inclusion in this directory is not an endorsement.